 |
|
|
| |
Primary results from MAESTRO-NASH a pivotal phase 3
52-week serial liver biopsy study in 966 patients with NASH and fibrosis
|
| |
| |
EASL 2023 Vienna June 21-24
Data from the 52-week first 1,000 patient portion of MAESTRO-NASH, together with data from MAESTRO-NAFLD-1, MAESTRO-NAFLD-OLE, Phase 2 and Phase 1 data, including safety parameters, will form the basis of the subpart H submission to FDA for accelerated approval of resmetirom for treatment of NASH.
|
| |
|
|
|
|
|
